CSPC Ouyi Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company that manufactures and markets both finished drugs and active pharmaceutical ingredients (APIs). The company, also known as "Ouyi," is a subsidiary of CSPC Pharmaceutical Group Limited (HKEX: 1093), a leading publicly traded pharmaceutical group based in China. CSPC Ouyi traces its origins back to 1938, established as Shijiazhuang No.1 Pharmaceutical Factory, and is headquartered in Shijiazhuang, Hebei Province, China. It employs approximately 3,000 individuals, while its parent company, CSPC Pharmaceutical Group, reported revenues of over $4 billion in 2024 and has approximately 21,400 employees.
CSPC Ouyi's operations encompass the research, development, manufacturing, and marketing of a diverse portfolio of over 200 formulated drug products, including tablets, capsules, granules, and parenteral solutions. These products address various therapeutic areas such as antibiotics, cardiovascular diseases, analgesic and anti-inflammatory conditions, and metabolic disorders. Key API products include azithromycin, indomethacin, levamlodipine maleate, and tramadol hydrochloride. The company also has multiple drugs in its pipeline, including late-stage candidates like pregabalin sustained-release tablets.
CSPC Ouyi Pharmaceutical Co., Ltd. is an active participant in patent litigation, demonstrating a two-way posture with both plaintiff and defendant roles. The company has been involved in two tracked U.S. patent cases. Its litigation includes appearing as a plaintiff in CSPC Pharmaceutical Group Limited et al. v. Ipsen Biopharm Ltd. before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office, initiated in January 2025. Concurrently, CSPC Ouyi is a defendant in IPSEN BIOPHARMACEUTICALS, INC. et al. v. CONJUPRO BIOTHERAPEUTICS, INC. et al. in the U.S. District Court for the District of New Jersey, a case that began in April 2024.
The involvement in these cases suggests competitive litigation within the pharmaceutical industry, particularly with Ipsen, potentially concerning rival drug products. The cases in both the PTAB and the District of New Jersey indicate that CSPC Ouyi engages in patent disputes across different judicial and administrative forums relevant to the pharmaceutical sector.